852 related articles for article (PubMed ID: 24573911)
1. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
[TBL] [Abstract][Full Text] [Related]
2. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
3. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.
Garris C; Jhingran P; Bass D; Engel-Nitz NM; Riedel A; Dennis G
J Med Econ; 2013; 16(5):667-77. PubMed ID: 23425294
[TBL] [Abstract][Full Text] [Related]
4. Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population.
Furst DE; Clarke A; Fernandes AW; Bancroft T; Gajria K; Greth W; Iorga SR
Lupus; 2013 Mar; 22(3):268-78. PubMed ID: 23340996
[TBL] [Abstract][Full Text] [Related]
5. Costs associated with severe and nonsevere systemic lupus erythematosus in Canada.
Clarke AE; Urowitz MB; Monga N; Hanly JG
Arthritis Care Res (Hoboken); 2015 Mar; 67(3):431-6. PubMed ID: 25185936
[TBL] [Abstract][Full Text] [Related]
6. Health care resource utilization and costs in a commercially insured population of patients with bipolar disorder type I and frequent psychiatric interventions.
Bagalman E; Muser E; Choi JC; Durden E; Macfadden W; Haskins JT; Dirani R
Clin Ther; 2011 Oct; 33(10):1381-1390.e4. PubMed ID: 22000656
[TBL] [Abstract][Full Text] [Related]
7. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population.
Li T; Carls GS; Panopalis P; Wang S; Gibson TB; Goetzel RZ
Arthritis Rheum; 2009 Jun; 61(6):755-63. PubMed ID: 19479688
[TBL] [Abstract][Full Text] [Related]
8. Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study.
Tanaka Y; Mizukami A; Kobayashi A; Ito C; Matsuki T
Int J Rheum Dis; 2018 Aug; 21(8):1609-1618. PubMed ID: 30146745
[TBL] [Abstract][Full Text] [Related]
9. A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus.
Kan H; Guerin A; Kaminsky MS; Yu AP; Wu EQ; Denio A; Priti J; Narayanan S; Molta C
J Med Econ; 2013; 16(6):793-800. PubMed ID: 23647447
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States.
Bell CF; Ajmera MR; Meyers J
Lupus; 2022 Feb; 31(2):202-211. PubMed ID: 35060407
[TBL] [Abstract][Full Text] [Related]
11. Direct cost of management and treatment of active systemic lupus erythematosus and its flares in Spain: the LUCIE Study.
Cervera R; Rúa-Figueroa I; Gil-Aguado A; Sabio JM; Pallarés L; Hernández-Pastor LJ; Iglesias M
Rev Clin Esp (Barc); 2013 Apr; 213(3):127-37. PubMed ID: 23398815
[TBL] [Abstract][Full Text] [Related]
12. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.
Laliberté F; Bookhart BK; Vekeman F; Corral M; Duh MS; Bailey RA; Piech CT; Lefebvre P
J Manag Care Pharm; 2009 May; 15(4):312-22. PubMed ID: 19422271
[TBL] [Abstract][Full Text] [Related]
13. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
Kariburyo F; Xie L; Sah J; Li N; Lofland JH
J Med Econ; 2020 Jan; 23(1):1-9. PubMed ID: 31589081
[No Abstract] [Full Text] [Related]
14. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
15. The cost to managed care of managing pulmonary hypertension.
Said Q; Martin BC; Joish VN; Kreilick C; Mathai SC
J Med Econ; 2012; 15(3):500-8. PubMed ID: 22313330
[TBL] [Abstract][Full Text] [Related]
16. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
[TBL] [Abstract][Full Text] [Related]
17. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
[TBL] [Abstract][Full Text] [Related]
18. Treatment costs and health care utilization for patients with bipolar disorder in a large managed care population.
Guo JJ; Keck PE; Li H; Jang R; Kelton CM
Value Health; 2008; 11(3):416-23. PubMed ID: 18179673
[TBL] [Abstract][Full Text] [Related]
19. Resource utilization and costs following hospitalization of patients with chronic heart failure in the US.
Korves C; Eldar-Lissai A; McHale J; Lafeuille MH; Hwa Ong S; Sheng Duh M
J Med Econ; 2012; 15(5):925-37. PubMed ID: 22502902
[TBL] [Abstract][Full Text] [Related]
20. The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States.
Bell CF; Huang SP; Cyhaniuk A; Averell CM
Lupus; 2023 Feb; 32(2):301-309. PubMed ID: 36542670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
